Director, Metabolic Disease Discovery Research @QuotientTx, translating somatic variants into therapies, views my own, part-time runner, full-time corgi walker
Joined November 2015
- Tweets70
- Following312
- Followers81
- Likes134
Bryan MacDonald retweeted
@VerveTx 3Q earnings:
1. VERVE-102 targeting PCSK9 being tested in Heart-2 trial
*treated 7 patients now across 2 dose levels (0.3 mg/kg and 0.45 mg/kg)
*well tolerated, no serious adverse events, no clinically significant lab abnormalities
*escalation to next dose after planned DSMB
*data disclosure planned in 1H 2025
2. VERVE-201 targeting ANGPTL3 - first patient has been dosed in Pulse-1 trial!
3. Continued progress on pre-clinical LPA product candidate
4. $540M in cash, runway through 2026
5. With two product candidates now in the clinic, 2025 should be an eventful year for Verve's vision 👇
ir.vervetx.com/news-releases…
Bryan MacDonald retweeted
Thrilled to announce that @US_FDA has cleared our
*investigational new drug (IND)* application
for VERVE-101
FDA reviewed our hold response which included:
1. interim clinical data from the ongoing heart-1 trial currently being conducted ex-U.S.
2. pre-clinical data to address their questions
Allows us to start heart-1 trial in US to test VERVE-101 in patients living with heterozygous familial hypercholesterolemia
See full release here: globenewswire.com/news-relea…
$VERV @VerveTx
Bryan MacDonald retweeted
Idea: 2016
Company: 2018
NHP data: 2020
1st patient dosed: 2022
1st human data for in vivo liver base editing in patients with heterozygous familial hypercholesterolemia and ASCVD
👇🏽
@American_Heart
@VerveTx
$VERV
Stay tuned!
Bryan MacDonald retweeted
@VerveTx approach to targets:
human genetics: heterozygous & homozygous deficiency -> protection from disease, tolerated & safe
human pharmacology: another Rx against target proven to work in patients
These validation criteria led to prioritization of PCSK9, ANGPTL3, & LPA
Sometimes during early drug development on enzymes, you find interesting new substrates. Sharing our recent bioRxiv where we report a new Corin atrial natriuretic peptide-converting enzyme substrate: Agouti-signaling protein (ASIP) biorxiv.org/content/10.1101/…
Here we identified the precise Corin cleavage site in Agouti-signaling protein (ASIP). Thanks to Nadine Elowe, Colin Garvie, Virendar Kaushik and @patrick_ellinor from CDoT and CVDi @broadinstitute
1
1
168
Bryan MacDonald retweeted
Shunkert and Kessler provide #editorial commentary on the potential for a vaccine targeting ADAMTS-7 to prevent atherosclerosis/in-stent restenosis #AHAJournals ahajrnls.org/3ylOqWs
Bryan MacDonald retweeted
UK's MHRA
has awarded VERVE-101 for Rx of heterozygous familial hypercholesterolemia an
Innovation Passport
under Innovative Licensing & Access Pathway (intended to accelerate time to market & patient access)
ir.vervetx.com/news-releases…
$VERV @VerveTx
Bryan MacDonald retweeted
Excited to share this preview on three exciting digit regeneration studies from the groups of @JessicaLehoczky @MarianRosL and Freda Miller. cell.com/cell-reports/fullte…
Bryan MacDonald retweeted
Nice graphical abstract from @escardio review on advances in dyslipidemia (L)
@vervetx mission (R)
Three pillars of lipoprotein risk - LDL, TRL, Lp(a)
We are developing a once-&-done medicine for each: PCSK9 (LDL), ANGPTL3 (LDL & TRL), and LPA (Lp(a))
academic.oup.com/eurheartj/a…
Bryan MacDonald retweeted
#OriginalResearch: A Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia @QingboX #AHAJournals ahajrnls.org/3VQvqsr
Interesting new paper out from Wei Kong showing positive effects in vivo from anti-ADAMTS7 antibodies raised to the human ADAMTS7 catalytic domain
Peptide Vaccine Against ADAMTS-7 Ameliorates Atherosclerosis and Postinjury Neointima Hyperplasia ahajournals.org/doi/10.1161/…
Bryan MacDonald retweeted
In @CircAHA, we publish today pre-clinical data for VERVE-101
Of note, @American_Heart tells us that for Scientific Sessions '22, this abstract the highest ranked one of all submitted from U.S.
#AHA22
Press release: globenewswire.com/news-relea…
Paper: ahajournals.org/doi/10.1161/…
Bryan MacDonald retweeted
Delighted to announce a
Clinical Trial Authorization (CTA) clearance
by UK MHRA (Medicines and Healthcare products Regulatory Agency)
for VERVE-101
as investigational Rx for patients with heterozygous familial hypercholesterolemia
ir.vervetx.com/news-releases…
$VERV @VerveTx
Bryan MacDonald retweeted
Excited to announce today:
development candidate for 2nd program
(VERVE-201 targeting the ANGPTL3 gene)
to treat homozygous FH as well as ASCVD
data to be presented by @amitvkhera @escardio 2022
Press release: ir.vervetx.com/news-releases…
Data: ir.vervetx.com/static-files/…
$VERV
Bryan MacDonald retweeted
Eventful few months
@VerveTx
*VERVE-101 1st patient dosed
*Evolution board, addition of Lonnel Coats & Bo Cumbo
*Add new target for base editing
*Collaboration with Vertex
*Follow-on financing
*Cash runway extended to 2H 2025
$VERV
ir.vervetx.com/news-releases…
Bryan MacDonald retweeted
2018: @VerveTx founded with concept of one-time Rx to lower LDL as low as possible for as long as possible
Today: we are announcing
dosing of *first patient* with VERVE-101,
an in vivo CRISPR base editing medicine
🙏 to patient volunteer
$VERV
globenewswire.com/news-relea…
Bryan MacDonald retweeted
And it’s about to get real 👌🏽
@VerveTx VERVE-101 Phase 1
ClinicalTrials.gov registration now live
A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease - Full Text View - ClinicalTrials.gov clinicaltrials.gov/ct2/show/…